EUVIMEDEUVIMED entdecken
Crossref

Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long‐term endpoint: The non‐Gaussian case

Leandro Garcia Barrado iD, Tomasz Burzykowski iD

Pharmaceutical Statistics · 2024

DOI: 10.1002/pst.2398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Leandro Garcia Barrado und 1 weiteren Autor:innen. Beteiligte Einrichtung: International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium. Hauptthemen laut MEDLINE: Endpoint Determination, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Service Public de Wallonie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In randomized clinical trials that use a long‐term efficacy endpoint, the follow‐up time necessary to observe the endpoint may be substantial. In such trials, an attractive option is to consider an interim analysis based solely on an early outcome that could be used to expedite the evaluation of treatment's efficacy. Garcia Barrado et al. ( Pharm Stat. 2022; 21: 209–219) developed a methodology that allows introducing such an early interim analysis for the case when both the early outcome and the long‐term endpoint are normally‐distributed, continuous variables. We extend the methodology to any combination of the early‐outcome and long‐term‐endpoint types. As an example, we consider the case of a binary outcome and a time‐to‐event endpoint. We further evaluate the potential gain in operating characteristics (power, expected trial duration, and expected sample size) of a trial with such an interim analysis in function of the properties of the early outcome as a surrogate for the long‐term endpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endpoint DeterminationRandomized Controlled Trials as TopicHumansTreatment OutcomeTime FactorsSample SizeResearch DesignData Interpretation, StatisticalModels, StatisticalInformation Sources

Stichwörter der Autor:innen

efficacy stoppinggroup‐sequential designinterim analysisrandomized clinical trialsurrogate endpoint

Autor:innen und Institutionen

  • International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
  • Institute of Statistics, Biostatistics, and Actuarial Sciences (ISBA), Louvain Institute for Data Analysis and Modeling, Louvain-la-Neuve, Belgium.
  • Data Science Institute, I-BioStat, Hasselt University, Hasselt, Belgium.

ORCID-Profile: Leandro Garcia Barrado, Tomasz Burzykowski

Förderung

  • Service Public de Wallonie

Zitieren

APA

Garcia Barrado, L., & Burzykowski, T. (2024). Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long‐term endpoint: The non‐Gaussian case. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2398

Vancouver

Garcia Barrado L, Burzykowski T. Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long‐term endpoint: The non‐Gaussian case. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2398

BibTeX
@article{GarciaBarrado2024,
  author = {Garcia Barrado, Leandro and Burzykowski, Tomasz},
  title = {Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long‐term endpoint: The non‐Gaussian case},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  doi = {10.1002/pst.2398}
}
Kostenlos starten →